Translating Knowledge
into Health

SAGEbio is pioneering a unique discovery-to-manufacturing technology platform, giving access to key biopharmaceuticals.

In-house developed vaccine advancing to clinical trials.
Discovery and development pipeline ranging from knowledge-based in silico design through to high quality production.
Working with leading research institutes and commercial partners to translate innovations into cutting edge therapeutics.
bt_bb_section_bottom_section_coverage_image

Vaccines beyond the limitations of mRNA formulations

Proprietary technology for safe, effective and stable vaccine compositions.
https://i0.wp.com/sagebio.tech/wp-content/uploads/2022/11/homapage-thumb.jpg.webp?resize=320%2C320&ssl=1

Therapeutics beyond the limitation of nature's sequence space

Modularity for unmatched integration and modification during discovery, design and development.
https://i0.wp.com/sagebio.tech/wp-content/uploads/2022/10/close-up-of-antibody.jpg?resize=320%2C320&ssl=1

Scalable production beyond the constraints of cellular expression

Cheap, fast and modular expression of pharmaceutical proteins.
https://i0.wp.com/sagebio.tech/wp-content/uploads/2022/11/home_Therapeutics.jpg?resize=320%2C320&ssl=1

Integrated discovery, design and development

Enabling pharmaceutical proteins from vaccines to multispecific biologics.

SAGEbio is developing novel subunit-type vaccines an using unique approach and with an initial focus on the CoVID-19 pandemic. The integrated platform facilitates the advancement of candidates into clinical trials. Future targets include:

Vaccines addressing persistent and emerging zoonotic threats.
Immunomodulators focusing on oncology targets and cell therapy approaches.
Modular and multispecific biologics providing solutions beyond current therapeutic strategies.

Expanding our Portfolio beyond Vaccines

Extending the SAGEbio full suite discovery-to-manufacturing technology platform by integrating knowledge gained from the current clinical phase candidate development.

Our proprietary discovery platform allows rapid identification of effective high-precision biomolecules. AI integration elicits optimized pharmaceutical parameters. A portfolio of GMP production and background in biopharmaceutical development facilitates partnering for clinical phases.

https://i0.wp.com/sagebio.tech/wp-content/uploads/2022/10/unnamed-e1667253051399.png?fit=640%2C122&ssl=1

Contact us at

info@SAGEbio.tech
One Broadway, 14th Fl., Cambridge, MA, USA
Ibn Sina Bldg., 4700 KAUST, 23955 Thuwal, KSA